Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
House rejects bill to require state plan coverage for weight-loss drugs and PCOS treatments; vote 50-50
Summary
Lawmakers debated a bill to require the state employees’ health plan to cover GLP-1 weight‑loss drugs and some treatments for polycystic ovary syndrome. After extended debate over cost, side effects and fiscal notes, House Bill 783 failed on a 50–50 vote.
House representatives on Thursday debated House Bill 783, which would have required the Montana state employee health plan to cover certain glucagon‑like peptide‑1 (GLP‑1) receptor agonists for people with class 3 obesity and for treatment of polycystic ovary syndrome (PCOS). Representative Rosenzweig introduced the bill, calling it a two‑year pilot limited to the state plan and urging members to send it to appropriations for further review.
The sponsor said the bill would allow doctors to prescribe GLP‑1 drugs ‘‘for patients with significant type 3 obesity risks or polycystic ovarian syndrome’’ and that the program would be reviewed after two years. Rosenzweig said the initial fiscal note overestimated cost because the original draft had broader coverage; she and…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
